Jazz Pharmaceuticals, Inc. - JAZZ STOCK NEWS

Jazz Pharmaceuticals (Nasdaq: JAZZ) reported a 9% revenue increase in 2020, totaling $2.36 billion, driven by successful product launches like Zepzelca and Xywav. GAAP net income for 2020 was $238.6 million, or $4.22 per diluted share, down from $523.4 million in 2019. The company projects 2021 revenues between $2.55 billion and $2.7 billion, emphasizing growth in neuroscience and oncology sectors. Additionally, Jazz is set to acquire GW Pharmaceuticals for $7.2 billion, aiming to enhance its neuroscience portfolio.

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced its participation in the Leerink 10th Annual Global Healthcare Conference. CEO Bruce Cozadd will present on February 24, 2021, at 1:40 p.m. EST. The presentation will include a business and financial update, accessible via a live audio webcast on the Jazz Pharmaceuticals website. An archive will be available for at least a week post-presentation. Jazz is focused on developing innovative medications in neuroscience and oncology, with a global presence serving patients in over 90 countries.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has completed the rolling submission for a supplemental New Drug Application (sNDA) to the FDA for Xywav™. This oral solution aims to treat adult patients with idiopathic hypersomnia, marking it as the first approved treatment in the U.S. for this condition. The application follows Fast Track designation received in September 2020 and was granted rolling submission in December 2020. Jazz plans to make this treatment available in Q4 2021, pending FDA approval. The prevalence of idiopathic hypersomnia is estimated to exceed 37,000 adults in the U.S.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will announce its 2020 fourth quarter and full year financial results on February 23, 2021, post market close. A live audio webcast will follow at 4:30 p.m. EST/ 9:30 p.m. GMT for a discussion on the results and company update. Interested parties can access the webcast on the Jazz Pharmaceuticals website. The company develops life-changing medicines in neuroscience and oncology, with a diverse portfolio serving patients in over 90 countries.

Jazz Pharmaceuticals has announced a $7.2 billion acquisition of GW Pharmaceuticals, valuing the company at $220 per American Depositary Share. The deal includes $200 in cash and $20 in Jazz shares, representing a premium of 50% over GW's recent stock price. Expected to close in Q2 2021, this acquisition aims to enhance Jazz's neuroscience portfolio with GW's lead product, Epidiolex, a treatment for severe epilepsy. The combined entity is projected to accelerate revenue growth, driven by a robust pipeline of 19 clinical programs focused on critical unmet patient needs.

Jazz Pharmaceuticals (Nasdaq: JAZZ) will webcast its corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:00 p.m. EST. CEO Bruce Cozadd will provide a business and financial update. The live audio webcast can be accessed on the Jazz Pharmaceuticals website and will be archived for at least a week afterward. The company focuses on developing life-changing medicines in neuroscience and oncology, and operates globally, serving patients in over 90 countries.

Jazz Pharmaceuticals has initiated the submission of a Biologics License Application (BLA) to the FDA for JZP-458, targeting acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in patients with hypersensitivity to E. coli-derived asparaginase. The BLA will be reviewed under the FDA's Real-Time Oncology Review program to expedite approval. JZP-458, a recombinant Erwinia asparaginase, received Fast Track designation in October 2019. The company anticipates launching JZP-458 by mid-2021, addressing significant patient needs.

Jazz Pharmaceuticals, in partnership with PharmaMar, announced results from the ATLANTIS Phase 3 study assessing Zepzelca™ (lurbinectedin) combined with doxorubicin for small cell lung cancer (SCLC) patients who progressed after platinum treatment. While the primary endpoint of overall survival was not met, key secondary analyses favored the combination. The study's safety profile was consistent with known data, showing favorable tolerability. The FDA has already granted accelerated approval for Zepzelca. Next steps include providing ATLANTIS data to the FDA for potential full approval.

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced the appointment of Jennifer Cook and Mark D. Smith, M.D. to its Board of Directors, effective December 1, 2020. Cook brings over 30 years of biopharmaceutical experience, while Smith is a recognized expert in health policy. The additions aim to enhance Jazz's strategy for transformative growth, leveraging their expertise to advance product development. Meanwhile, board members Elmar Schnee and Paul Berns will step down before the 2021 annual meeting. Jazz has launched three new products this year, indicating strong commercial activity.